Michael S Klnch

Title: Michael S Klnch: Innovator in Cancer Immunotherapy

Introduction

Michael S Klnch is a notable inventor based in Laytonsville, MD (US). He has made significant contributions to the field of cancer immunotherapy through his innovative research and patent work. His expertise lies in the development of T-cell epitopes that have the potential to enhance immune responses against cancer.

Latest Patents

Michael S Klnch holds a patent for "EphA2 T cell epitopes and uses therefor." This patent includes peptides corresponding to specific fragments of the human EphA2 protein, which contain one or more T-cell epitopes. The EphA2 T-cell epitopes are particularly useful in assays, such as ELISPOT assays, that can determine and quantify a patient's immune responsiveness to EphA2. Furthermore, these epitopes can be utilized in methods to modulate a patient's immune reactivity to EphA2, which is crucial for treating cancers that overexpress EphA2, such as renal cell carcinoma (RCC). Additionally, the EphA2 epitopes can be employed to vaccinate patients against EphA2 using in vivo or ex vivo methods. Michael S Klnch has 1 patent to his name.

Career Highlights

Michael S Klnch is affiliated with the University of Pittsburgh, where he continues to advance his research in immunotherapy. His work has garnered attention for its potential applications in cancer treatment, particularly in enhancing the immune system's ability to target and destroy cancer cells.

Collaborations

Michael collaborates with Walter J Storkus, a fellow researcher in the field. Their combined efforts aim to further the understanding and application of T-cell epitopes in cancer therapies.

Conclusion

Michael S Klnch is a pioneering inventor whose work in T-cell epitopes holds promise for improving cancer treatment strategies. His contributions to the field of immunotherapy are significant and continue to impact patient care.